Belgian Dx Shop OncoMethylome to File IPO; Sale May Shed Light on Market s Appetite for Dx Plays | GenomeWeb

Belgian molecular diagnostic company OncoMethylome is planning to file an initial public offering "in the coming months" in Europe, an event that may serve as a barometer of sorts for the state of the molecular diagnostics market on that continent.

OncoMethylome, which hopes to list on both the Eurolist and Euronext Brussels and Amsterdam exchanges, plans to use the cash from the IPO to expand and accelerate its pipeline of molecular diagnostics, the firm said in a statement. OncoMethylome has no products on the market yet.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.